Felix Rabito, MD
Gastroenterology · Covington, LANPI 1619939410
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by QOL Medical, LLC at 53.0% of the total. Reporting peaked in 2021 at $10,417 and has fallen 64.5% since, to $3,701 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,122 payments — averaging $36.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- QOL Medical, LLC$22K
- AbbVie$5K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Gilead$1K
- plus $8K from 46 others
What the payments were for
- Speaking & faculty fees$20,40049%
- Food & beverage$20,61050%
- Education$3651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sucraid$20,974
- Skyrizi$370
- Rinvoq$265
- Tremfya$244
- STELARA$242
- ZEPOSIA$224
- OCALIVA$213
- CONMED BILIARY$132
- CONMED HEMOSTASIS$132
- CONMED GENERATORS$132
- DUPIXENT$127
- EXALT MODEL D CONTROLLER$122
- XIFAXAN$118
- IQIRVO$115
- OMVOH$109
- VOQUEZNA$109
- Humira$105
- GENERAL POLYPECTOMY$103
How this compares
$41,375 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 19 | $74,418 |
| CreonLipase/Protease/Amylase | 33 | $66,749 |
| XifaxanRifaximin | 12 | $34,315 |
| Mesalamine | 38 | $24,124 |
| LinzessLinaclotide | 22 | $12,355 |
| VoqueznaVonoprazan Fumarate | 18 | $10,603 |
| MovantikNaloxegol Oxalate | 12 | $8,822 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 48 | $7,995 |
| Pantoprazole Sodium | 497 | $5,126 |
| Dexlansoprazole DrDexlansoprazole | 14 | $5,046 |
| Colesevelam Hcl | 53 | $3,864 |
| Entecavir | 23 | $3,293 |
| Ursodiol | 13 | $2,690 |
| Lansoprazole | 14 | $2,079 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 12 | $1,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $4,896 | $79,10455 claims |
| Madrigal PharmaceuticalsRezdiffra | $25 | $74,41819 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,856 | $34,31512 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $272 | $10,60318 claims |
| Redhill Biopharma Inc.Movantik | $127 | $8,82212 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $169 | $7,99548 claims |
| Braintree Laboratories, Inc.Suflave | $156 | $1,49012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Covington
- Nathaniel RanneyCovington$392K
- Lemuel JenkinsCovington$99K
- Lawrence GenslerCovington$31K
- Brandon BrousseCovington$16K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.